Last Updated: 15 Oct 2024
Executive Summary
Mesoblast Ltd (MESO) is a biopharmaceutical company that develops and markets allogeneic cellular drugs. The company has a market capitalization of $1.13 billion and is headquartered in Melbourne, Australia. MESO's latest stock price is $9.93, which is below its 52-week high of $11.05 and above its 52-week low of $1.61.
Company Overview
Mesoblast is a clinical-stage biopharmaceutical company that develops allogeneic cellular therapies for the treatment of severe inflammatory diseases. The company's lead product candidate, remestemcel-L, is a mesenchymal stem cell therapy that is being developed for the treatment of acute respiratory distress syndrome (ARDS) and chronic heart failure. Mesoblast also has a number of other product candidates in development, including MSC-100-IV, which is being developed for the treatment of severe sepsis and COVID-19.
Fundamental Analysis
Mesoblast's financial performance has been mixed in recent years. The company has reported losses in each of the past four fiscal years. In fiscal 2023, Mesoblast reported a loss of $56.1 million on revenue of $5.9 million. The company's operating margin was -12.49% and its return on assets was -0.0541%.
Mesoblast's balance sheet is relatively strong. The company has $179.3 million in cash and equivalents and no debt. The company's book value is $0.421 per share.
Technical Analysis
Mesoblast's stock price has been in a downtrend since early 2023. The stock has broken below its 50-day and 200-day moving averages. The relative strength index (RSI) is below 30, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Mesoblast is negative. The stock is in a downtrend and has broken below its key moving averages. The RSI is also below 30, which indicates that the stock is oversold.
Long Term Outlook
The long-term outlook for Mesoblast is more positive. The company has a number of promising product candidates in development, including remestemcel-L and MSC-100-IV. If these products are successful, they could generate significant revenue for the company.
Analyst Recommendations
Analysts are mixed on Mesoblast. Two analysts have a buy rating on the stock, while zero analysts have a strong buy rating, a hold rating, a sell rating, or a strong sell rating. The average analyst target price is $11.50.
